experienceCustom
monoclonal antibody
developmentPrimary
monoclonal antibodies
Secondary monoclonal
antibodiesImmunoaffinity
SYnAbs' vision is to fill the gap on the marketplace for innovative monoclonal antibodies against poor immunogenic compounds and complex homologous antigens. Targeting transmembrane proteins (GPCRs, ion channels, transporters), steroids, small molecules, toxins, lipids and polysaccharides (on fungi and bacteria), SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat-LOU species to generate unique monoclonal antibodies of extreme specificity and higher affinity.